Search clinical trials for: selumetinib (oral)

Total 8277 results

AstraZeneca

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Solid Tumours

United Kingdom
AstraZeneca

Completed

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Solid Tumours

United States
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

Solid Tumors

United States
AstraZeneca
Merck Sharp & Dohme LLC

Recruiting

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE)

Neurofibromatosis Type 1

United States, Spain, Germany, Russian Federation, Japan, Italy, Netherlands
AstraZeneca

Completed

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Healthy Volunteers Bioavailability Study

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)

United States
AstraZeneca

Approved for marketing

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

NF type1 With Inoperable Plexiform Neurofibromas

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

Solid Tumours

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Neurofibromatosis Type 1

United States, Spain, Poland, Russian Federation
AstraZeneca

Withdrawn

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study (PROTECT)

Neurofibromatosis Type 1 | Plexiform Neurofibromas | Post-operative

China
The Christie NHS Foundation Trust
AstraZeneca; University of Manchester

Completed

MEK Inhibitor and Thoracic Radiotherapy Trial (MEKRT)

Non Small Cell Lung Cancer

United Kingdom
AstraZeneca

Completed

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

Healthy Volunteers Bioequivalence or Bioavailability Study

United Kingdom
Children's Hospital Medical Center, Cincinnati
AstraZeneca

Active, not recruiting

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)

Glioma | Ependymoma | Meningioma | Neurofibromatosis 2 | Vestibular Schwannoma

United States
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
National Cancer Institute (NCI)

Active, not recruiting

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Primary Central Nervous System Neoplasm | Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Myelodysplastic Syndromes | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Withdrawn

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Neoplasms, Nerve Tissue | Peripheral Nervous System Diseases | Heredodegenerative Disorders, Nervous System | Neurofibromatosis 1
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Primary Peritoneal Carcinoma | Low Grade Ovarian Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Primary Peritoneal Low Grade Serous Adenocarcinoma | Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
AstraZeneca
Merck Sharp & Dohme LLC

Completed

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Neurofibromatosis 1 | Neurofibroma Plexiform

China
AstraZeneca

Completed

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

Healthy Volunteers Pharmacokinetic Study

United Kingdom
AstraZeneca

Completed

Selumetinib Paediatric NF1 Japan Study

Neurofibromatosis Type 1

Japan
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Optic Nerve Glioma

United States
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Cancer | Non Small Cell Lung Cancer

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
AstraZeneca

Completed

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT)

Neurofibromatosis Type 1 | Optic Nerve Glioma | Plexiform Neurofibroma

United Kingdom
National Cancer Institute (NCI)

Completed

Selumetinib in Cancers With BRAF Mutations

Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | KRAS NP_004976.2:p.G12R

United States
Haihe Biopharma Co., Ltd.

Completed

Single Dose Glumetinib in Healthy Chinese Male Subjects

Healthy Volunteers

China
National Cancer Institute (NCI)

Completed

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sheffield Teaching Hospitals NHS Foundation Trust
AstraZeneca; University of Sheffield; Cancer Research UK; University of Birmingham and other collaborators

Terminated

A Study of Selumetinib in Patients With Kaposi's Sarcoma (SCART)

AIDS-related Kaposi's Sarcoma

United Kingdom
AstraZeneca

Completed

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,

Japan
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Liver and Intrahepatic Biliary Tract Cancer

United States
National Cancer Institute (NCI)

Terminated

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma

United States
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
National Cancer Institute (NCI)

Completed

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
Haihe Biopharma Co., Ltd.

Unknown

A Phase I Study of SCC244

Advanced Solid Tumor

China
Haihe Biopharma Co., Ltd.

Unknown

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Advanced Solid Tumor

China
University of Alabama at Birmingham
Children's Hospital of Philadelphia; Congressionally Directed Medical Research...

Not yet recruiting

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 (NF114)

Neurofibromatosis 1 | Plexiform Neurofibroma
AstraZeneca

Terminated

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA)

Differentiated Thyroid Cancer

United States, Denmark, Italy, Sweden, Poland, Brazil, France, Germany
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Queen Mary University of London
AstraZeneca; Cancer Research UK

Unknown

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK)

Squamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRAS

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
University of Alabama at Birmingham
United States Department of Defense

Not yet recruiting

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Sarcoma | NF1 | MPNST

United States
National Cancer Institute (NCI)

Withdrawn

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Stage II Gallbladder Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder... and other conditions
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer

Search clinical trials for: selumetinib (oral)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations